Benzodiazepine Use Disorder: Misuse, Dependence, and Treatment

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

Benzodiazepine use disorder is a clinically significant pattern of benzodiazepine use characterized by impaired control and continued use despite harm. It belongs to the broader diagnostic family of sedative, hypnotic, or anxiolytic use disorders. A person can become physically dependent on a prescribed benzodiazepine without developing a use disorder, and a person can misuse benzodiazepines without meeting the full diagnostic criteria. Recognizing these distinctions determines whether care should center on medication safety, treatment of an underlying illness, addiction-focused intervention, medically supervised withdrawal management, or a combination of these approaches. The 2025 Joint Clinical Practice Guideline on Benzodiazepine Tapering explicitly treats physical dependence and benzodiazepine use disorder as distinct clinical states.

Benzodiazepines include medications such as alprazolam, clonazepam, diazepam, lorazepam, and temazepam. Their clinical effects can be valuable for selected anxiety, sleep, seizure, and other conditions, while repeated exposure may lead to physiological adaptation, sedation-related harm, hazardous co-use, and, in some individuals, compulsive patterns of use. The US Food and Drug Administration requires class-wide boxed warnings addressing misuse, addiction, physical dependence, withdrawal, and potentially fatal combinations with other central nervous system depressants.

What Is Benzodiazepine Use Disorder?

The clinical diagnosis concerns a problematic, persistent pattern of behavior involving benzodiazepines. It is identified through consequences and loss of control rather than by a particular prescription, medication name, blood concentration, or withdrawal symptom alone. The diagnostic question is whether use has become an impairing pattern involving features such as taking more than intended, repeated unsuccessful attempts to reduce use, craving, hazardous use, neglect of obligations, or continuing despite recurrent harm. An assessment must consider the reasons for treatment, the person's actual use, associated impairments, and whether symptoms are attributable to another condition.

In the DSM-5-TR classification, benzodiazepine-related addiction symptoms are evaluated under sedative, hypnotic, or anxiolytic use disorder. This larger diagnostic category includes substances beyond benzodiazepines. In ICD-11, disorders due to sedatives, hypnotics, or anxiolytics are organized using different diagnostic concepts, including harmful patterns of use and dependence syndrome. Clinicians should name the applicable classification rather than assuming the different systems use interchangeable definitions. The World Health Organization's ICD-11 clinical guidance supplies the relevant international framework.

Use, misuse, hazardous use, and use disorder

Benzodiazepine use means exposure to one of these medications, whether prescribed or otherwise obtained. Appropriate prescribed use may carry physiological risks that need monitoring. Misuse refers to taking a medicine in a way other than directed or without one's own valid prescription, a heterogeneous category encompassing self-treatment, excessive or more frequent use, and use for desired psychoactive effects. Hazardous or risky use emphasizes the likelihood of harm in a particular context, such as driving while impaired or combining sedatives. A use disorder denotes a defined clinical syndrome established by assessment against diagnostic criteria.

These categories overlap but are not equivalent. A person may take an extra tablet during an episode of anxiety and require a review of prescribing and coping strategies without satisfying a use-disorder diagnosis. Another person may repeatedly seek pills from multiple sources, experience substantial impairment, and continue using despite consequences, making evaluation for a disorder especially important. Research on the epidemiology of benzodiazepine misuse shows that motivations, sources, intensity, and associated risks vary widely, and many episodes of misuse reflect attempts to manage anxiety or sleep disturbance.

Physical dependence, tolerance, withdrawal, and addiction

Physical dependence is a physiological adaptation to repeated drug exposure. When the medication is reduced too quickly or stopped, the nervous system may produce withdrawal symptoms. Tolerance is a reduction in effect with repeated exposure, although it develops unevenly across benzodiazepine effects and across individuals. Withdrawal is a set of symptoms following reduced exposure, and its severity depends on multiple factors, including the medication, duration, pattern of use, and coexisting health conditions.

Addiction describes a clinically meaningful pattern of impaired control and continued use despite adverse consequences. The presence of withdrawal or tolerance alone does not establish addiction, especially when a medication has been taken in accordance with appropriate medical supervision. This distinction is central to the ASAM-led tapering guideline and prevents people receiving legitimate treatment from being incorrectly labeled as having a substance use disorder. Conversely, someone who shows pronounced compulsive use may need addiction care even if they report little overt withdrawal.

Clinical Symptoms and Diagnostic Criteria

A clinical interview explores the eleven DSM-5-TR substance-use domains during a twelve-month period: using larger amounts or for longer than intended; unsuccessful efforts to cut down; substantial time spent obtaining, using, or recovering from the substance; craving; repeated failure to fulfill obligations; persistent interpersonal problems related to use; activities reduced or abandoned; recurrent use in physically hazardous situations; use despite recognized physical or psychological problems; tolerance; and withdrawal. Clinically significant impairment or distress and at least two applicable criteria are required. The familiar severity bands are mild with two or three criteria, moderate with four or five, and severe with six or more. Under medical supervision, tolerance and withdrawal are not counted when they are solely the expected consequences of appropriate prescribed use.

Diagnosis also requires clinical judgment about time course, medication indications, dose-taking behavior, external circumstances, and the meaning of reported symptoms. Craving can involve a strong urge to obtain relief from anxiety, sleep loss, or medication withdrawal; a clinician must establish whether this is part of a broader maladaptive pattern. Continued use despite harm must be assessed in context rather than inferred from the mere fact that treatment lasted longer than originally expected. The potential need for a safer prescribing plan can exist before a use disorder is diagnosed.

Clinical examples and their interpretation

A patient who has taken a stable, prescribed benzodiazepine for years, remains functionally stable, and develops withdrawal symptoms after a rapid interruption may have physical dependence without benzodiazepine use disorder. Care should address medication risk, symptoms of the original condition, and the safety of any contemplated change.

A different patient may regularly obtain benzodiazepines outside medical care, take them in escalating or unplanned patterns, miss important obligations, and continue after injuries or dangerous episodes. These observations support a structured assessment for a use disorder and for possible alcohol or opioid use. A third patient may take a higher prescribed dose during episodic insomnia, indicating misuse and possible harm, yet require additional evidence before a disorder can be diagnosed. The diagnostic distinction alters the clinical response; neither reflexively diagnosing addiction nor ignoring impairment serves the patient.

Screening, assessment, and diagnosis

Screening is the initial identification of possible substance-related risk. Questions about prescriptions, nonprescribed medications, alcohol, opioids, sleep medicines, sedating antihistamines, cannabis products, and other substances can identify situations needing further evaluation. General substance-screening tools may guide the interview, but a score alone does not diagnose benzodiazepine use disorder. The subsequent clinical assessment examines the patient's actual behavior, medical and psychiatric conditions, prescribed and obtained substances, current intoxication or withdrawal risk, safety, and functioning. Diagnosis is the informed application of established criteria after considering alternative explanations.

A high-quality assessment also evaluates falls, impaired driving, cognitive symptoms, prior withdrawal seizures, overdose history, suicidality, employment and family effects, and access to medicines from more than one source. Prescription drug monitoring program information may inform prescribing safety where available; discrepancies call for a respectful discussion rather than automatic assumptions. The 2025 Joint Guideline recommends regular risk-benefit review and consideration of nonprescribed benzodiazepines and interacting substances.

How Benzodiazepines Affect the Brain

Benzodiazepines are positive allosteric modulators at gamma-aminobutyric acid type A (GABA-A) receptors. By increasing the effect of the inhibitory neurotransmitter GABA at responsive receptors, they can decrease neuronal excitability and produce anxiolytic, sedative, anticonvulsant, and muscle-relaxing effects. The response is shaped by receptor subtype, drug pharmacokinetics, prior exposure, the treated condition, and interactions with other substances. This shared pharmacology does not mean all benzodiazepines have identical onset, duration, withdrawal characteristics, or effects in an individual.

Repeated exposure may prompt neuroadaptations that change the response to the drug and to its absence. When benzodiazepine action decreases, a previously adapted nervous system may temporarily exhibit heightened arousal, autonomic symptoms, anxiety, or sleep disturbance. The resulting relief from taking another dose can reinforce use through negative reinforcement: drug-taking temporarily removes an aversive state. Reward-related processes, expectations, learned cues, and social context can contribute as well. No single neural mechanism determines who develops a use disorder, and physical adaptation by itself is insufficient evidence of compulsive addiction.

Relief, learning, and the development of compulsive behavior

Some people initially experience marked relief from panic, agitation, insomnia, or distress. Repetition can establish associations between the medication, rapid relief, particular settings, and feelings of control. Over time, anticipatory anxiety and withdrawal-related discomfort may strengthen medication-seeking behavior. In other cases, benzodiazepines are taken to intensify the effects of other drugs, blunt stimulant effects, or pursue sedation and intoxication. Motivations can shift within the same person, requiring continuing assessment rather than a fixed stereotype. The systematic review by Votaw and colleagues documents this heterogeneity in misuse motives and patterns.

The neurobiology of dependence and the psychology of addiction should be studied together. Receptor adaptation may explain aspects of withdrawal, while decision-making, expectations, reinforcement, emotional regulation, access, environmental stressors, and co-occurring substance use influence whether drug-taking becomes persistently harmful. Evidence for these mechanisms comes from different kinds of studies; mechanistic plausibility alone does not establish a deterministic causal pathway for an individual patient.

How Common Are Misuse and Benzodiazepine Use Disorder?

Population estimates vary with year, country, age group, the survey's wording, and the diagnostic criteria used. In analyses of US national survey data from 2015–2016, approximately 30.5 million adults reported benzodiazepine use, 5.2 million reported misuse, and approximately half a million met the study's benzodiazepine use-disorder definition during the preceding year. The published epidemiological analysis estimated that about 1.5% of adults who reported benzodiazepine use met its use-disorder definition. These are historical, survey-based findings, not estimates of the current 2026 burden; ascertainment, diagnostic operationalization, and unreported use limit direct comparisons.

The important pattern is that benzodiazepine exposure, misuse, and clinical use disorder occur at substantially different frequencies. Conflating them inflates disease estimates and obscures the clinical needs of people with physical dependence alone. Underreporting, recall bias, differential access to health care, and changes in nonprescribed drug markets further complicate surveillance. Epidemiological associations with co-occurring psychiatric symptoms and other drug use do not by themselves establish that a benzodiazepine prescription caused addiction.

Why Benzodiazepine Use Disorder Develops

The risk of developing a benzodiazepine-related problem is shaped by medication exposure, individual vulnerabilities, co-occurring symptoms, drug availability, and social context. Factors repeatedly associated with misuse include a history of other substance use disorders, psychological distress, access to prescriptions or nonprescribed medications, and use of multiple psychoactive substances. The 2019 systematic epidemiological review synthesizes these patterns while emphasizing that observational associations have multiple possible explanations.

Sleep disturbance and anxiety can create legitimate pressure to seek relief. Depression, trauma-related symptoms, chronic pain, unstable housing, relationship conflict, and limited access to effective treatment may influence use patterns. These contextual variables vary across populations, and the relative contributions of genes, learning, social environment, and medication exposure remain difficult to estimate for any one patient. Risk assessment therefore combines clinical history and present behavior instead of relying on a single personality trait, symptom, or presumed motive.

The interaction with other substance use disorders

Benzodiazepine misuse often occurs alongside alcohol, opioids, stimulants, or other drugs. Sometimes the medication is used for sleep or anxiety while another substance is being used for a different purpose; sometimes it is used deliberately to modify intoxication or withdrawal. Co-use increases the need for coordinated medical evaluation. In particular, simultaneous exposure to opioids, alcohol, or other sedating agents creates major overdose and respiratory risks. The FDA boxed-warning communication describes these interactions and the importance of coordinated care.

Risks, Impairments, and Medical Complications

Benzodiazepine-associated harm spans impaired attention, slowed reaction time, sedation, falls, confusion, memory disturbance, impaired driving, and interactions with other depressants. Risk depends on the person's age, comorbidities, medication exposure, other medications, and the environment. Clinical studies report associations between prolonged benzodiazepine exposure and adverse outcomes, but causality can be difficult to separate from the conditions for which these medications were prescribed. Risk-benefit decisions require the benefits of symptom control to be considered alongside current harms, alternative treatments, and withdrawal risk. ASAM's 2025 guideline emphasizes repeated individualized review.

Overdose and polysubstance exposure

The combination of benzodiazepines with opioids is particularly dangerous because both can contribute to central nervous system and respiratory depression. Alcohol and other sedating medicines may increase impairment. Opioid-related overdose is treated as an emergency; naloxone can reverse opioid effects and should be administered when opioid overdose is suspected, although it does not reverse benzodiazepine sedation itself. Professional emergency assessment, breathing support, and observation remain essential, particularly with suspected mixed ingestion. The FDA warns explicitly about fatal combinations.

Emergency help is needed for slow or absent breathing, inability to awaken a person, repeated loss of consciousness, seizures, severe confusion with imminent danger, or suspected overdose. Where naloxone is available and opioid exposure is possible, a bystander can use it according to its product instructions while arranging emergency services. A person who improves after naloxone still requires professional assessment because other sedatives may remain active and respiratory depression can recur. Never rely on sleeping off severe intoxication.

Withdrawal and abrupt discontinuation

Withdrawal can include anxiety, insomnia, restlessness, tremor, perceptual disturbances, and autonomic symptoms, and severe episodes may involve delirium or seizures. Symptoms can overlap with recurrence of the condition originally treated. Some individuals report persistent or fluctuating symptoms after a medication reduction or cessation, and clinical interpretation can be difficult. The FDA safety communication recognizes potentially prolonged reactions and life-threatening seizures after abrupt discontinuation or overly rapid reduction.

The clear clinical principle is that individuals who may be physically dependent should not abruptly stop benzodiazepines or attempt rapid unsupervised withdrawal. Severity is not safely predicted from medication name or self-assessed willpower. The 2025 multisociety guideline recommends medically supervised, individualized decisions and consideration of inpatient or medically managed residential care when severe or complicated withdrawal risk cannot be managed safely as an outpatient. The separate clinical subject of withdrawal and tapering involves detailed care-setting and monitoring decisions; the present article addresses their place within the broader diagnosis and treatment of benzodiazepine use disorder.

Differential Diagnosis and Co-Occurring Conditions

A central diagnostic challenge is distinguishing withdrawal-related anxiety or insomnia from relapse of a preexisting anxiety or sleep disorder. Abrupt symptom onset following a medication reduction, qualitatively new symptoms, and accompanying physical manifestations may increase suspicion for withdrawal. However, individual circumstances require examination of other medical and psychiatric explanations. NICE guideline NG215 specifically directs clinicians to evaluate symptom timing and quality and to distinguish withdrawal from recurrence of underlying illness.

Other differential considerations include medication adverse effects without compulsive use, alcohol withdrawal, intoxication from other sedatives, mood disorders, primary anxiety disorders, trauma-related symptoms, sleep disorders, neurocognitive impairment, and medically caused confusion. In an acutely impaired person, clinicians prioritize vital signs, immediate safety, possible mixed ingestion, and medical stabilization over formal long-term diagnosis. Drug testing may assist selected clinical questions, but results depend on the assay and cannot establish loss of control, motivation, or a use-disorder diagnosis on their own.

Anxiety, insomnia, and benzodiazepine prescribing

The therapeutic role of benzodiazepines in anxiety disorders has its own evidence and risk-benefit literature. A person receiving them for anxiety should have the underlying condition assessed and treated on its own merits. The related encyclopedia article Benzodiazepines for Anxiety: Benefits, Risks, Dependence, and Clinical Caution examines appropriate prescribing considerations, while this article owns the distinct question of a diagnosed benzodiazepine use disorder and its treatment. The article Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity provides the broader cross-condition context.

Evidence-Based Treatment: A Coordinated Clinical Model

Treatment begins with diagnostic clarification, patient priorities, immediate safety, and a plan that addresses both benzodiazepine-related behavior and the conditions influencing it. When a use disorder is present, evidence-informed care can combine substance-use counseling, cognitive behavioral strategies, treatment of co-occurring psychiatric disorders, medication-safety management, social supports, and a supervised taper when clinically indicated. The combination and care setting depend on the person's goals, psychiatric and medical stability, substance exposures, and withdrawal risk. A taper addresses physiological exposure and withdrawal risk; addiction treatment addresses impaired control and the broader conditions sustaining harmful use.

Shared decisions and therapeutic alliance

Effective care depends on a nonjudgmental assessment of why benzodiazepines are being taken, what benefits the person experiences, what harms have occurred, and what changes are feasible. Abrupt prescription cessation in a physically dependent person can create substantial danger and undermine care. Shared decision-making, careful monitoring, and clinical coordination are recommendations of the ASAM-led 2025 guideline and NICE NG215. A person who has used medicines outside a prescription should be offered a candid safety discussion and a therapeutic path rather than exclusion from care.

Medication review and supervised tapering

For an individual with established physical dependence, a qualified clinician evaluates whether continued benzodiazepine treatment is justified and whether gradual reduction is appropriate. The plan may account for the original medical indication, the patient's response to previous changes, access to follow-up, other sedating substances, and seizure history. Long-duration treatment or previous withdrawal complications may require more intensive support. Some individuals can receive outpatient care; others need a higher level of monitoring. Guideline-based tapering is individualized, can be paused or adjusted when clinically needed, and should account for symptoms and functioning rather than imposing a universal schedule. The 2025 Joint Clinical Practice Guideline is the governing clinical reference for these decisions.

Detoxification or withdrawal stabilization alone is not comprehensive treatment for a use disorder. The psychological, social, and behavioral conditions associated with harmful use still require assessment, and some people need ongoing support after medication reduction. Conversely, some patients who do not have a use disorder still need medically supervised tapering because physical dependence and the risks of prolonged exposure may be substantial.

Cognitive behavioral therapy and psychological treatment

Cognitive behavioral therapy (CBT) can help address anxiety, insomnia, conditioned medication-taking, catastrophic interpretations of bodily sensations, avoidance, relapse triggers, and skills for tolerating distress. Techniques are selected according to the clinical presentation; CBT for insomnia differs in emphasis from exposure-based treatment of panic and addiction-focused relapse-prevention strategies. Psychological care can support medication reduction without replacing necessary medical monitoring. NICE NG215 advises considering group CBT during benzodiazepine withdrawal.

A Cochrane review of psychosocial interventions found moderate-certainty evidence in its reviewed trials that CBT combined with tapering increased short-term benzodiazepine discontinuation compared with tapering alone. Its pooled estimates suggested benefit soon after treatment and at three months, while longer-term effects were uncertain. Many studies enrolled long-term users with physiological dependence, so the findings cannot automatically be generalized to people with severe, compulsive, polysubstance benzodiazepine use disorder. The treatment literature's population definitions, co-occurring conditions, follow-up periods, and retention outcomes need careful attention.

Motivational interviewing and other collaborative behavioral approaches may improve engagement and help explore the patient's goals, but evidence that they independently cause benzodiazepine discontinuation is more limited. The same Cochrane review judged the available motivational-interviewing evidence very uncertain because trials were small and estimates imprecise. Treating such approaches as universally proven for benzodiazepine use disorder would overstate the evidence; their role depends on the patient's formulation and the broader substance-use treatment plan.

Medicines proposed to facilitate discontinuation

There is no broadly established, benzodiazepine-use-disorder-specific replacement medication comparable to the well-supported medications used for opioid use disorder. Investigators have studied a variety of drugs to ease withdrawal symptoms or facilitate discontinuation, but evidence is inconsistent, often of low certainty, and not sufficient to justify routine self-directed use. A Cochrane review of pharmacological interventions included 38 randomized trials and concluded that no firm efficacy conclusions could be drawn because of bias, imprecision, and limited safety reporting. NICE guidance advises against valproate or buspirone for benzodiazepine withdrawal and cautions against substituting another dependence-forming medicine solely to treat withdrawal symptoms.

Medications for independently diagnosed anxiety, depression, insomnia, seizure disorders, or other conditions may be appropriate according to their own evidence base. Their use should be distinguished from an evidence-established pharmacotherapy for benzodiazepine use disorder. Adjunctive or specialized approaches are clinical decisions for qualified professionals, and the existence of a small trial does not itself establish efficacy or safety.

Integrated care for alcohol, opioid, and other substance disorders

Co-occurring substance disorders demand a coordinated treatment plan. In people with opioid use disorder, medications such as buprenorphine or methadone have established benefits, and co-occurring benzodiazepine exposure raises the need for careful risk management. The 2025 Joint Guideline states that clinicians should not disrupt medications for opioid use disorder solely because of benzodiazepine use or tapering. Treating the opioid disorder and assessing benzodiazepine risk together is generally safer than creating avoidable gaps in treatment. Assessment should also consider alcohol use, respiratory disease, sleep apnea, suicide risk, and other sedating medications.

If a person uses nonprescribed benzodiazepines, uncertainty about pill contents is relevant to overdose prevention; drug supply may include other sedatives or opioids. Clinicians should assess risk based on actual exposure, offer appropriate harm-reduction resources, and plan follow-up. Naloxone access is relevant when opioid exposure is possible, even though it does not directly reverse benzodiazepines. Support for safer behavior, treatment access, and continuity of care belongs alongside diagnostic treatment.

Prevention, Prescribing Safety, and Harm Reduction

Prevention includes careful selection of patients and indications, periodic reassessment of benefits and harms, using medicines as directed, secure storage, and early recognition of escalating or unsafe use. Clinicians should review medications that depress the central nervous system, inquire about alcohol and nonprescribed drug exposure, and consider safer evidence-based treatments for chronic anxiety or insomnia when appropriate. Patients can discuss changes openly before altering medication routines. The FDA calls for risk assessment, education, and gradual clinician-supervised discontinuation when indicated.

Harm-reduction approaches address risks even when a person is not yet ready or able to stop use. Examples include avoiding simultaneous sedatives and alcohol, understanding respiratory danger from opioid combinations, having emergency contacts and access to emergency services, and receiving clinical support for withdrawal risk. People should never share prescription benzodiazepines or assume a nonprescribed tablet contains the claimed drug. Programs and settings differ in available services, and harm reduction should be incorporated into broader person-centered care.

Special Populations and Contextual Considerations

Older adults and medically vulnerable people

Older adults may face heightened risks of sedation, falls, fractures, delirium, and interactions with multiple medications. Cognitive impairment, frailty, impaired kidney or liver function, sleep apnea, and chronic respiratory disorders may affect risk-benefit evaluation and monitoring. Discontinuation still requires consideration of physical dependence: a high baseline risk from continuing the medication does not make abrupt withdrawal safe. The ASAM-led guideline specifically addresses older adults and complicated medical presentations.

Adolescents and young adults

Assessment in adolescents and younger adults should explore nonprescribed pills, peer access, developmental context, impulsive behavior, school functioning, depression, suicide risk, and concurrent use of alcohol, opioids, or other drugs. Validated assessments and engagement strategies appropriate to age and capacity matter. Nonmedical use warrants safety intervention, while formal diagnosis still follows clinical criteria. Family or caregiver involvement is individualized according to age, confidentiality requirements, safeguarding considerations, and the patient's needs.

Pregnancy and postpartum care

Pregnancy requires coordinated assessment of medication exposure, untreated maternal illness, withdrawal risks, fetal and neonatal considerations, and access to appropriate obstetric and psychiatric care. Automatic abrupt cessation may create hazards; treatment decisions require individualized specialist evaluation. The 2025 multidisciplinary guideline includes pregnancy-specific considerations and stresses balancing continued-use risk against taper-related risk. A use-disorder diagnosis, physical dependence, and medication exposure should be documented as separate clinical dimensions.

Psychiatric vulnerability, self-harm, and trauma

Anxiety, insomnia, trauma-related symptoms, depression, and other mental health conditions may complicate misuse or tapering. Assessment includes current suicidality, self-harm history, severe mood symptoms, psychosis when relevant, and access to safe care. Acute suicidal intent, severe agitation with medical instability, or psychotic confusion requires urgent professional evaluation. Trauma-informed practice can improve engagement without assuming that all problematic use has the same psychological origin. The separate Anxiety and Substance Use article examines the broader relationship between psychiatric symptoms and substance use.

Recovery, Remission, and Long-Term Outcomes

Recovery is a continuing process of improved health, safety, functioning, autonomy, and connection, with goals and pathways reflecting the person's circumstances and preferences. For a person with diagnosed benzodiazepine use disorder, meaningful outcomes may include resolution of compulsive use, reduced hazardous exposure, engagement with effective mental health treatment, improved family and occupational functioning, and sustained remission. For another patient with physiological dependence but no use disorder, a successful outcome might be safer ongoing treatment or the gradual resolution of dependence under clinical care. These trajectories should be evaluated according to the original clinical formulation.

Remission is a diagnostic term reflecting the absence of most active disorder criteria during a defined period, subject to the relevant classification's rules. Recurrence of symptoms can occur and should trigger reassessment of triggers, untreated disorders, medication access, withdrawal effects, and social stressors. Relapse is a common informal term for return to harmful use, but a single episode does not convey its severity or all of its implications. Continuity of care and the opportunity to re-engage improve the chance of addressing renewed problems without stigma.

Follow-up care can include treatment for insomnia or anxiety, recovery-oriented behavioral strategies, monitoring of substance exposures, practical support, and coordination among medical and mental health clinicians. Outcomes research is harder to generalize when studies combine people who were appropriately prescribed long-term benzodiazepines with those who meet stringent compulsive-use disorder criteria. Reporting patient-centered outcomes such as symptoms, quality of life, retention, and functioning is necessary alongside reporting medication cessation alone.

What the Evidence Establishes and What Remains Uncertain

Established evidence supports the clinical separation of physical dependence from use disorder, the risk of severe withdrawal after abrupt discontinuation in dependent people, serious interactions with opioids and other depressants, and the value of shared decisions and careful medical supervision. These conclusions are strongly reflected in FDA warnings, the 2025 multisociety guideline, and NICE.

Evidence of moderate certainty supports CBT added to a taper for improving some short-term discontinuation outcomes in selected study populations, while long-term effects and applicability to severe benzodiazepine use disorder remain less certain. Evidence for specific medications to facilitate discontinuation is generally low or very low certainty, with inconsistent safety data. Epidemiological evidence establishes associations between misuse, psychiatric symptoms, and polysubstance use, but the observational designs often cannot identify the direction or magnitude of causal effects. Cochrane's psychosocial review, pharmacological review, and the systematic epidemiology review support these gradations.

Questions deserving further high-quality research include interventions specifically evaluated in patients meeting current DSM-5-TR benzodiazepine use-disorder criteria, optimal treatment integration when other substance disorders are present, long-term functional outcomes, disparities in access to specialized care, and patient-important responses to various support models. Newer digital or AI-assisted supports should be evaluated as clinical interventions only when trials establish safety and effectiveness for the relevant population; generic chatbots cannot be presumed to provide evidence-based treatment or emergency monitoring.

Frequently Asked Questions

Is benzodiazepine dependence the same as addiction?

No. Physical dependence is an adaptation that may occur during appropriate prescribed treatment. Addiction or benzodiazepine use disorder involves a clinically significant pattern of impaired control and continued use despite harm. Clinicians evaluate each condition separately because stopping a physically dependent patient's medication abruptly can be dangerous even when there is no use disorder. The 2025 Joint Guideline makes this distinction explicit.

Can prescribed benzodiazepines lead to a use disorder?

Yes, a minority of exposed individuals may develop problematic, compulsive use, and prescribed status does not exclude a diagnosis when the applicable clinical criteria are met. Most people with physical dependence do not automatically meet use-disorder criteria. The FDA requires prescribers to discuss the possibility of misuse and addiction as well as dependence and withdrawal.

What are warning signs that benzodiazepine use is becoming harmful?

Warning signs can include repeatedly taking more than intended, uncontrolled efforts to reduce use, seeking medication outside agreed care, continued use despite injuries or serious impairment, combining sedatives, or neglecting valued activities. Each sign warrants assessment rather than a conclusion from a checklist alone. Immediate concern is greater when there is overdose risk, loss of consciousness, respiratory impairment, or severe withdrawal symptoms.

Is it safe to stop benzodiazepines suddenly?

Someone who is physically dependent can experience severe and occasionally life-threatening withdrawal, including seizures, after abrupt discontinuation. A clinician should assess withdrawal risk and plan any necessary medication change. Emergency medical services are appropriate for seizures, delirium, severe confusion, suspected overdose, or breathing difficulty. General online schedules cannot replace individualized medical care.

What treatments have the best evidence?

The strongest direct guidance concerns clinical assessment, avoidance of abrupt cessation in dependent patients, individualized medically supervised tapering when indicated, management of co-occurring conditions, and collaborative care. Trials suggest CBT can improve short-term discontinuation rates when combined with tapering in selected groups. There is no universally validated medication that cures benzodiazepine use disorder; evidence for adjunct medications remains uncertain. ASAM, NICE, and Cochrane are the central references.

How is benzodiazepine use disorder different from benzodiazepine withdrawal?

The use disorder concerns the long-term behavioral and clinical syndrome of impaired control and harm. Withdrawal is a physiological response to reducing or stopping exposure. Withdrawal can occur with or without a use disorder, and its medical management does not alone treat the underlying behavioral syndrome. The diagnostic distinction changes treatment goals and safety planning.

When should someone seek emergency care?

Call local emergency medical services for seizures, markedly reduced responsiveness, slowed or absent breathing, suspected mixed-drug overdose, severe delirium, or a psychiatric crisis involving imminent danger. If opioids may be involved and naloxone is available, follow its product instructions while seeking emergency care. Anyone considering a change to regular benzodiazepine use should discuss the plan with a qualified clinician before making it.

Related Articles

Benzodiazepines for Anxiety: Benefits, Risks, Dependence, and Clinical Caution explores therapeutic indications, medication decisions, and clinical risks for anxiety treatment.

Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity examines overlap between psychiatric symptoms, coping behaviors, and substance-related conditions.

Substance- or Medication-Induced Anxiety Disorder: Causes, Diagnosis, and Treatment reviews anxiety symptoms arising in temporal relation to substance exposure or withdrawal.

Benzodiazepine Withdrawal and Tapering: Clinical Safety — withdrawal risks, individualized supervised tapering, and safety considerations.

Physical Dependence vs Addiction: Tolerance, Withdrawal, and Compulsive Use — how physiological adaptation differs from compulsive substance use and diagnostic disorder.

Substance Intoxication vs Withdrawal: Symptoms and Clinical Assessment — acute intoxication, withdrawal syndromes, differential assessment, and triage.

References

American Society of Addiction Medicine and partner medical societies. (2025). Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Benzodiazepine Risks Outweigh Benefits. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-025-09499-2

Baandrup, L., Ebdrup, B. H., Rasmussen, J. Ø., Lindschou, J., Gluud, C., and Glenthøj, B. Y. (2018). Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database of Systematic Reviews, CD011481. https://doi.org/10.1002/14651858.CD011481.pub2

Darker, C. D., Sweeney, B. P., Barry, J. M., Farrell, M. F., and Donnelly-Swift, E. (2015). Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database of Systematic Reviews, CD009652. https://www.cochrane.org/evidence/CD009652_psychosocial-interventions-reduce-sedative-use-abuse-and-dependence

National Institute for Health and Care Excellence. (2022). Medicines associated with dependence or withdrawal symptoms: Safe prescribing and withdrawal management for adults (NG215). https://www.nice.org.uk/guidance/ng215/chapter/Recommendations

Olfson, M., King, M., and Schoenbaum, M. (2015). Benzodiazepine use in the United States. JAMA Psychiatry, 72(2), 136–142. https://doi.org/10.1001/jamapsychiatry.2014.1763

US Food and Drug Administration. (2020). FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class

Votaw, V. R., Geyer, R., Rieselbach, M. M., and McHugh, R. K. (2019). The epidemiology of benzodiazepine misuse: A systematic review. Drug and Alcohol Dependence. https://pmc.ncbi.nlm.nih.gov/articles/PMC6639084/

World Health Organization. (2024). Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. https://www.who.int/publications/i/item/9789240077263